• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Treatment options for refractory ulcerative colitis: Small molecules, big effects.难治性溃疡性结肠炎的治疗选择：小分子，大作用。
United European Gastroenterol J. 2024 Jun;12(5):539-540. doi: 10.1002/ueg2.12585. Epub 2024 May 7.
2
Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.一名溃疡性结肠炎患者在接受维多珠单抗治疗期间出现结节性血管炎。
Australas J Dermatol. 2022 Feb;63(1):131-132. doi: 10.1111/ajd.13754. Epub 2021 Nov 24.
3
Vedolizumab for the treatment of ulcerative colitis.维多珠单抗用于治疗溃疡性结肠炎。
Expert Opin Biol Ther. 2016;16(1):129-35. doi: 10.1517/14712598.2016.1121231. Epub 2015 Dec 9.
4
Vedolizumab for the treatment of ulcerative colitis.维多珠单抗用于治疗溃疡性结肠炎。
Expert Rev Gastroenterol Hepatol. 2016;10(2):165-75. doi: 10.1586/17474124.2016.1123618. Epub 2015 Dec 15.
5
Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure.对于一名依赖皮质类固醇且先前抗TNF-α药物治疗失败的溃疡性结肠炎患者，采用血细胞分离术联合维多珠单抗进行联合治疗。
Dig Liver Dis. 2018 Apr;50(4):415-417. doi: 10.1016/j.dld.2018.01.124. Epub 2018 Feb 1.
6
Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.维多珠单抗成功治疗一名16岁难治性溃疡性结肠炎男孩。
J Crohns Colitis. 2016 Mar;10(3):373-4. doi: 10.1093/ecco-jcc/jjv205. Epub 2015 Nov 15.
7
Response to vedolizumab for children with steroid-refractory Ulcerative Colitis unresponsive to anti-TNF.维多珠单抗对难治性溃疡性结肠炎儿童抗TNF治疗无效者的疗效。
Acta Paediatr. 2019 Jul;108(7):1359-1360. doi: 10.1111/apa.14765. Epub 2019 Mar 21.
8
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.英夫利昔单抗治疗难治性或不耐受性溃疡性结肠炎的临床疗效。
United European Gastroenterol J. 2020 Feb;8(1):91-98. doi: 10.1177/2050640619895361. Epub 2019 Dec 12.
9
Treatment of ulcerative colitis with infliximab: are we there yet?英夫利昔单抗治疗溃疡性结肠炎：我们做到了吗？
J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):247-9. doi: 10.1097/00005176-200403000-00005.
10
Recurrent COVID-19 in a Patient With Ulcerative Colitis on Vedolizumab Therapy.接受维多珠单抗治疗的溃疡性结肠炎患者复发性新型冠状病毒肺炎
J Crohns Colitis. 2021 Jul 5;15(7):1244-1245. doi: 10.1093/ecco-jcc/jjaa259.

引用本文的文献

1
Anemoside B4 alleviates ulcerative colitis by attenuating intestinal oxidative stress and NLRP3 inflammasome via activating aryl hydrocarbon receptor through remodeling the gut microbiome and metabolites.芍药苷B4通过重塑肠道微生物群和代谢产物激活芳烃受体，减轻肠道氧化应激和NLRP3炎性小体，从而缓解溃疡性结肠炎。
Redox Biol. 2025 Jun 28;85:103746. doi: 10.1016/j.redox.2025.103746.
2
Metformin Ameliorates Ulcerative Colitis Through Inhibiting NLRP3 Inflammasome Activation.二甲双胍通过抑制NLRP3炎性小体激活改善溃疡性结肠炎。
J Inflamm Res. 2025 Feb 5;18:1773-1786. doi: 10.2147/JIR.S503033. eCollection 2025.

本文引用的文献

1
Strategies for targeting cytokines in inflammatory bowel disease.靶向细胞因子治疗炎症性肠病的策略。
Nat Rev Immunol. 2024 Aug;24(8):559-576. doi: 10.1038/s41577-024-01008-6. Epub 2024 Mar 14.
2
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.对比托法替布和乌司奴单抗作为难治性溃疡性结肠炎三线治疗药物的疗效：一项多中心国际研究。
United European Gastroenterol J. 2024 Jun;12(5):543-551. doi: 10.1002/ueg2.12492. Epub 2024 Feb 28.
3
1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.1 年托法替布对比乌司奴单抗治疗抗肿瘤坏死因子治疗失败的溃疡性结肠炎患者的疗效比较。
Inflamm Bowel Dis. 2024 Mar 1;30(3):395-401. doi: 10.1093/ibd/izad087.
4
Precision Medicine in Inflammatory Bowel Diseases.炎症性肠病中的精准医学
Front Pharmacol. 2021 Apr 13;12:653924. doi: 10.3389/fphar.2021.653924. eCollection 2021.
5
Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.联合组织学和内镜终点与乌司奴单抗治疗溃疡性结肠炎患者疗效的关系。
Gastroenterology. 2020 Dec;159(6):2052-2064. doi: 10.1053/j.gastro.2020.08.037. Epub 2020 Aug 25.
6
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.中重度活动型溃疡性结肠炎患者的一线和二线药物治疗：一项更新的网络荟萃分析。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6. doi: 10.1016/j.cgh.2020.01.008. Epub 2020 Jan 13.
7
Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.基于人群队列的成人溃疡性结肠炎自然史：系统评价。
Clin Gastroenterol Hepatol. 2018 Mar;16(3):343-356.e3. doi: 10.1016/j.cgh.2017.06.016. Epub 2017 Jun 16.

Treatment options for refractory ulcerative colitis: Small molecules, big effects.

作者信息

Marafini Irene, Roseira Joana, Duijvestein Marjolijn

机构信息

Gastroenterology Unit, Policlinico Universitario Tor Vergata, Rome, Italy.

Gastroenterology Department - unidade local de saúde do Algarve, unidade de Portimão, Portimão, Portugal.

出版信息

United European Gastroenterol J. 2024 Jun;12(5):539-540. doi: 10.1002/ueg2.12585. Epub 2024 May 7.

DOI:10.1002/ueg2.12585
PMID:38713604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11176894/
Abstract
摘要